“Whoa! It's like Spotify but for academic articles.”

Instant Access to Thousands of Journals for just $40/month

Get 2 Weeks Free

Treatment of schizophrenia with ergot derivatives



213 66 66 3 3 C. A. Tamminga M. H. Schaffer Experimental Therapeutics Branch, National Institute of Neurological and Communicative Disorders and Stroke National Institutes of Health 20205 Bethesda MD USA Manteno Mental Health Center Manteno Illinois USA Department of Psychiatry University of Chicago 60637 Chicago Ill. USA Abstract Seven neuroleptic-free schizophrenic patients received bromocriptine and eight schizophrenic patients received CF 25-397, both ergot derivatives with dopamine agonist activity. Psychosis failed to improve in response to either drug at the relatively low doses administered. Unlike the antipsychotic property of apomorphine at low dose levels, neither of these ergot drugs improved schizophrenic symptomatology.



PsychopharmacologySpringer Journals

Published: Dec 1, 1979

DOI: 10.1007/BF00428312

Free Preview of First Page

Loading next page...

You're reading a free preview. Subscribe to read the entire article.

And millions more from thousands of peer-reviewed journals, for just $40/month

Get 2 Weeks Free

To be the best researcher, you need access to the best research

  • With DeepDyve, you can stop worrying about how much articles cost, or if it's too much hassle to order — it's all at your fingertips. Your research is important and deserves the top content.
  • Read from thousands of the leading scholarly journals from Springer, Elsevier, Nature, IEEE, Wiley-Blackwell and more.
  • All the latest content is available, no embargo periods.